EDAP TMS SA, a global leader in therapeutic ultrasound, today announced financial results for the first quarter ended March 31, 2011, demonstrating growth across the board. All financial figures are expressed in U.S. dollar amounts.
Total revenue for the first quarter 2011 increased by 12.1 percent to $6.8 million compared to $5.9 million reported for the first quarter of 2010, reflecting strong lithotripsy device sales.
“Our innovative lithotripsy product line continues to be well received by the global urology community as exemplified by the strong reception received at the recent EAU, JUA and AUA meetings. During the first quarter, we sold seven lithotripsy devices as we continue to increase market share. At the beginning of the second quarter 2011, we have a strong pipeline of projects and continue to promote and penetrate new markets with our innovative and unique range of lithotripters,” Marc Oczachowski, EDAP’s CEO stated in the press release.
Gross profit for the first quarter 2011 increased by 15.2 percent to $2.7 million compared to $2.3 million reported for the comparable quarter of 2010. Gross profit margin was 40.7 percent in the first quarter 2011, compared to 39.6 percent in the year ago period.
Operating expenses were $3.7 million for the first quarter 2011, down 14.6 percent from $4.2 million reported for the same period 2010. EDAP reported an operating loss of $932,000 for the first quarter 2011, compared to $1.9 million in the first quarter of 2010.
Net income for the first quarter of 2011 was $295,000, or $0.02 per share, compared to a net loss of $3.5 million, or $(0.33) per share in the first quarter of 2010.
At March 31, 2011, EDAP reported cash and cash equivalents, including short-term treasury investments, of $8.6 million.
For more information visit edap-tms.com
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.